{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:00:09Z","timestamp":1793505609615,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T00:00:00Z","timestamp":1690070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T00:00:00Z","timestamp":1690070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1245\/s10434-023-13973-8","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T23:01:49Z","timestamp":1690066909000},"page":"7803-7813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma"],"prefix":"10.1245","volume":"30","author":[{"given":"Vahan","family":"Kepenekian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Sgarbura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kusamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,23]]},"reference":[{"issue":"2","key":"13973_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/path.1700120212","volume":"12","author":"J Miller","year":"1908","unstructured":"Miller J, Wynn WH. A malignant tumour arising from the endothelium of the peritoneum, and producing a mucoid ascitic fluid. J Pathol Bacteriol. 1908;12(2):267\u201378. https:\/\/doi.org\/10.1002\/path.1700120212.","journal-title":"J Pathol Bacteriol."},{"key":"13973_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.02.011","author":"S Kusamura","year":"2020","unstructured":"Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2020. https:\/\/doi.org\/10.1016\/j.ejso.2020.02.011.","journal-title":"Eur J Surg Oncol."},{"key":"13973_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cncr.32870","volume":"126","author":"Group CCW","year":"2020","unstructured":"Group CCW. The Chicago consensus on peritoneal surface malignancies: management of peritoneal mesothelioma. Cancer. 2020;126:1. https:\/\/doi.org\/10.1002\/cncr.32870.","journal-title":"Cancer."},{"issue":"6","key":"13973_CR4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/annonc\/mdl345","volume":"18","author":"P Boffetta","year":"2007","unstructured":"Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18(6):985\u201390. https:\/\/doi.org\/10.1093\/annonc\/mdl345.","journal-title":"Ann Oncol."},{"issue":"6","key":"13973_CR5","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","volume":"20","author":"SH Moolgavkar","year":"2009","unstructured":"Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973\u20132005. Cancer Causes Control. 2009;20(6):935\u201344. https:\/\/doi.org\/10.1007\/s10552-009-9328-9.","journal-title":"Cancer Causes Control."},{"issue":"10","key":"13973_CR6","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1200\/jop.2016.011908","volume":"12","author":"PH Sugarbaker","year":"2016","unstructured":"Sugarbaker PH, Turaga KK, Alexander HR, Deraco M, Hesdorffer M. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncology Pract. 2016;12(10):928\u201335. https:\/\/doi.org\/10.1200\/jop.2016.011908.","journal-title":"J Oncology Pract."},{"issue":"7","key":"13973_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/bf01225271","volume":"118","author":"M Markman","year":"1992","unstructured":"Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin. 1992;118(7):547\u201350. https:\/\/doi.org\/10.1007\/bf01225271.","journal-title":"J Cancer Res Clin."},{"issue":"6","key":"13973_CR8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s10434-999-0582-6","volume":"6","author":"BJ Park","year":"1999","unstructured":"Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol. 1999;6(6):582\u201390. https:\/\/doi.org\/10.1007\/s10434-999-0582-6.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"13973_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/jso.10255","volume":"83","author":"M Deraco","year":"2003","unstructured":"Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol. 2003;83(3):147\u201353. https:\/\/doi.org\/10.1002\/jso.10255.","journal-title":"J Surg Oncol."},{"issue":"36","key":"13973_CR10","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/jco.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237\u201342. https:\/\/doi.org\/10.1200\/jco.2009.23.9640.","journal-title":"J Clin Oncol."},{"issue":"1","key":"13973_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1245\/s10434-020-08324-w","volume":"19","author":"Group CCW","year":"2020","unstructured":"Group CCW. The Chicago consensus on peritoneal surface malignancies: management of peritoneal mesothelioma. Ann Surg Oncol. 2020;19(1):1\u20136. https:\/\/doi.org\/10.1245\/s10434-020-08324-w.","journal-title":"Ann Surg Oncol."},{"key":"13973_CR12","doi-asserted-by":"publisher","unstructured":"Participants LAR of PD\u2013 L. Current practice of Latin American centers in the treatment of peritoneal diseases with cytoreductive surgery with HIPEC. Eur J Surg Oncol. 2018;44(11):1800\u20131804. https:\/\/doi.org\/10.1016\/j.ejso.2018.06.029","DOI":"10.1016\/j.ejso.2018.06.029"},{"issue":"30","key":"13973_CR13","doi-asserted-by":"publisher","first-page":"6906","DOI":"10.3748\/wjg.v22.i30.6906","volume":"22","author":"Y Li","year":"2016","unstructured":"Li Y, Zhou YF, Liang H, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World J Gastroenterol. 2016;22(30):6906\u201316. https:\/\/doi.org\/10.3748\/wjg.v22.i30.6906.","journal-title":"World J Gastroenterol."},{"issue":"5","key":"13973_CR14","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1590\/0100-69912017005016","volume":"44","author":"TP Batista","year":"2017","unstructured":"Batista TP, Sarmento BJQ, Loureiro JF, et al. A proposal of Brazilian Society of Surgical Oncology (BSSO\/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. Rev Col Bras Cir. 2017;44(5):530\u201344.","journal-title":"Rev Col Bras Cir."},{"key":"13973_CR15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3978-x","author":"JH Helm","year":"2014","unstructured":"Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2014. https:\/\/doi.org\/10.1245\/s10434-014-3978-x.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"13973_CR16","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","volume":"25","author":"V Verma","year":"2018","unstructured":"Verma V, Sleightholm RL, Rusthoven CG, et al. Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival. Ann Surg Oncol. 2018;25(7):2018\u201326. https:\/\/doi.org\/10.1245\/s10434-018-6499-1.","journal-title":"Ann Surg Oncol."},{"issue":"15","key":"13973_CR17","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","volume":"49","author":"D Baratti","year":"2013","unstructured":"Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49(15):3140\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2013.05.027.","journal-title":"Eur J Cancer."},{"issue":"9","key":"13973_CR18","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ejso.2006.05.009","volume":"32","author":"TD Yan","year":"2006","unstructured":"Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(9):948\u201353. https:\/\/doi.org\/10.1016\/j.ejso.2006.05.009.","journal-title":"Eur J Surg Oncol."},{"issue":"13","key":"13973_CR19","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1245\/s10434-015-4498-z","volume":"22","author":"M Deraco","year":"2015","unstructured":"Deraco M, Cabras A, Baratti D, Kusamura S. Immunohistochemical evaluation of minichromosome maintenance protein 7 (MCM7), topoisomerase II\u03b1, and Ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray. Ann Surg Oncol. 2015;22(13):4344\u201351. https:\/\/doi.org\/10.1245\/s10434-015-4498-z.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"13973_CR20","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1245\/s10434-015-4962-9","volume":"23","author":"S Kusamura","year":"2016","unstructured":"Kusamura S, Mesa PAT, Cabras A, Baratti D, Deraco M. The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2016;23(5):1468\u201373. https:\/\/doi.org\/10.1245\/s10434-015-4962-9.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"13973_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1245\/s10434-008-0219-1","volume":"16","author":"D Baratti","year":"2009","unstructured":"Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M. Diffuse malignant peritoneal mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2009;16(2):463\u201372. https:\/\/doi.org\/10.1245\/s10434-008-0219-1.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"13973_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jamcollsurg.2012.04.023","volume":"215","author":"KI Votanopoulos","year":"2012","unstructured":"Votanopoulos KI, Ihemelandu C, Shen P, Stewart JH, Russell GB, Levine EA. Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg. 2012;215(3):412\u20137. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2012.04.023.","journal-title":"J Am Coll Surg."},{"issue":"5","key":"13973_CR23","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1245\/s10434-014-3977-y","volume":"22","author":"C Ihemelandu","year":"2014","unstructured":"Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol. 2014;22(5):1680\u20135. https:\/\/doi.org\/10.1245\/s10434-014-3977-y.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"13973_CR24","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ejso.2015.07.004","volume":"41","author":"Y Huang","year":"2015","unstructured":"Huang Y, Alzahrani NA, Liauw W, Morris DL. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2015;41(10):1373\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2015.07.004.","journal-title":"Eur J Surg Oncol."},{"issue":"3","key":"13973_CR25","first-page":"1","volume":"12","author":"RL Dedrick","year":"1985","unstructured":"Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol. 1985;12(3):1\u20136.","journal-title":"Semin Oncol."},{"issue":"6","key":"13973_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/0277-5379(90)90137-i","volume":"26","author":"G Los","year":"1990","unstructured":"Los G, McVie JG. Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer Clin Oncol. 1990;26(6):755\u201362. https:\/\/doi.org\/10.1016\/0277-5379(90)90137-i.","journal-title":"Eur J Cancer Clin Oncol."},{"key":"13973_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/978-1-4613-1247-5_26","volume":"82","author":"PH Sugarbaker","year":"1996","unstructured":"Sugarbaker PH, Averbach AM, Jacquet P, Stephens AD, Stuart OA. Peritoneal carcinomatosis: principles of management. Canc Treat. 1996;82:415\u201321. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_26.","journal-title":"Canc Treat."},{"key":"13973_CR28","doi-asserted-by":"publisher","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. In: Peritoneal carcinomatosis: principles of management, vol 82, 1996. pp.53\u201363. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_4","DOI":"10.1007\/978-1-4613-1247-5_4"},{"issue":"2","key":"13973_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","volume":"7","author":"WP Ceelen","year":"2010","unstructured":"Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2010;7(2):108\u201315. https:\/\/doi.org\/10.1038\/nrclinonc.2009.217.","journal-title":"Nat Rev Clin Oncol."},{"issue":"5","key":"13973_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1080\/02656736.2017.1291999","volume":"33","author":"L Lemoine","year":"2017","unstructured":"Lemoine L, Sugarbaker P, Speeten KVD. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. Int J Hyperth. 2017;33(5):582\u201392. https:\/\/doi.org\/10.1080\/02656736.2017.1291999.","journal-title":"Int J Hyperth."},{"issue":"13","key":"13973_CR31","doi-asserted-by":"publisher","first-page":"9098","DOI":"10.1245\/s10434-021-10193-w","volume":"28","author":"A Bhatt","year":"2021","unstructured":"Bhatt A, de Hingh I, Speeten KVD, et al. HIPEC methodology and regimens: the need for an expert consensus. Ann Surg Oncol. 2021;28(13):9098\u2013113. https:\/\/doi.org\/10.1245\/s10434-021-10193-w.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"13973_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-4613-1245-1_5","volume":"81","author":"HR Alexander","year":"1996","unstructured":"Alexander HR, Fraker DL. Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin. Cancer Treat Res. 1996;81(5):41\u201350. https:\/\/doi.org\/10.1007\/978-1-4613-1245-1_5.","journal-title":"Cancer Treat Res."},{"issue":"6","key":"13973_CR33","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1251::AID-CNCR27>3.0.CO;2-3","volume":"83","author":"DL Bartlett","year":"1998","unstructured":"Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer. 1998;83(6):1251\u201361.","journal-title":"Cancer."},{"issue":"24","key":"13973_CR34","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/jco.2003.04.150","volume":"21","author":"AL Feldman","year":"2003","unstructured":"Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560\u20137. https:\/\/doi.org\/10.1200\/jco.2003.04.150.","journal-title":"J Clin Oncol."},{"issue":"10","key":"13973_CR35","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1177\/000313480106701019","volume":"67","author":"BW Loggie","year":"2001","unstructured":"Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67(10):999\u20131003.","journal-title":"Am Surg."},{"issue":"3","key":"13973_CR36","first-page":"29","volume":"7","author":"N Jairath","year":"1994","unstructured":"Jairath N, Weinstein J. The Delphi methodology (Part one): a useful administrative approach. Can J Nurs Admin. 1994;7(3):29\u201342.","journal-title":"Can J Nurs Admin."},{"issue":"4","key":"13973_CR37","first-page":"7","volume":"7","author":"N Jairath","year":"1994","unstructured":"Jairath N, Weinstein J. The Delphi methodology (Part two): a useful administrative approach. Can J Nurs Admin. 1994;7(4):7\u201320.","journal-title":"Can J Nurs Admin."},{"issue":"7454","key":"13973_CR38","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ Clin Res Ed. 2004;328(7454):1490. https:\/\/doi.org\/10.1136\/bmj.328.7454.1490.","journal-title":"BMJ Clin Res Ed."},{"issue":"4","key":"13973_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jso.21059","volume":"98","author":"S Kusamura","year":"2008","unstructured":"Kusamura S, Baratti D, Younan R, Deraco M. The Delphi approach to attain consensus in methodology of local regional therapy for peritoneal surface malignancy. J Surg Oncol. 2008;98(4):217\u20139. https:\/\/doi.org\/10.1002\/jso.21059.","journal-title":"J Surg Oncol."},{"key":"13973_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.03.012","author":"RJ Lurvink","year":"2019","unstructured":"Lurvink RJ, Villeneuve L, Govaerts K, et al. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on pseudomyxoma peritonei and peritoneal mesothelioma. Eur J Surg Oncol. 2019. https:\/\/doi.org\/10.1016\/j.ejso.2019.03.012.","journal-title":"Eur J Surg Oncol."},{"key":"13973_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1245\/s10434-022-12990-3","volume":"2023","author":"S Kusamura","year":"2022","unstructured":"Kusamura S, Bhatt A, Hubner M, et al. The PSOGI international consensus on HIPEC regimens for peritoneal malignancies: methodology. Ann Surg Oncol. 2022;2023:1\u201312. https:\/\/doi.org\/10.1245\/s10434-022-12990-3.","journal-title":"Ann Surg Oncol."},{"key":"13973_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-023-01728-6","author":"V Kepenekian","year":"2023","unstructured":"Kepenekian V, Sgarbura O, Marchal F, et al. Peritoneal mesothelioma: systematic review of hyperthermic intraperitoneal chemotherapy (HIPEC) protocol outcomes. Indian J Surg Oncol. 2023. https:\/\/doi.org\/10.1007\/s13193-023-01728-6.","journal-title":"Indian J Surg Oncol."},{"issue":"1","key":"13973_CR43","first-page":"391","volume":"24","author":"D Kyziridis","year":"2019","unstructured":"Kyziridis D, Hristakis C, Kalakonas A, et al. Ten-year experience with peritoneal mesothelioma. J BUON. 2019;24(1):391\u20136.","journal-title":"J BUON."},{"key":"13973_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02656736.2018.1434902","volume":"58","author":"SNS Gilani","year":"2018","unstructured":"Gilani SNS, Mehta A, Garc\u00eda-Fadrique A, et al. Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. Int J Hyperth. 2018;58:1\u20137. https:\/\/doi.org\/10.1080\/02656736.2018.1434902.","journal-title":"Int J Hyperth."},{"issue":"8","key":"13973_CR45","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3109\/02656736.2015.1075071","volume":"31","author":"K Stamou","year":"2015","unstructured":"Stamou K, Tsamis D, Pallas N, et al. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature. Int J Hyperth. 2015;31(8):850\u20136. https:\/\/doi.org\/10.3109\/02656736.2015.1075071.","journal-title":"Int J Hyperth."},{"issue":"1","key":"13973_CR46","first-page":"9","volume":"69","author":"M Robella","year":"2014","unstructured":"Robella M, Vaira M, Mellano A, et al. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC. Minerva Chir. 2014;69(1):9\u201315.","journal-title":"Minerva Chir."},{"issue":"2","key":"13973_CR47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/jso.21177","volume":"99","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99(2):109\u201313. https:\/\/doi.org\/10.1002\/jso.21177.","journal-title":"J Surg Oncol."},{"issue":"2","key":"13973_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1245\/aso.2006.03.045","volume":"13","author":"M Deraco","year":"2006","unstructured":"Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13(2):229\u201337. https:\/\/doi.org\/10.1245\/aso.2006.03.045.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"13973_CR49","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1046\/j.1365-2168.2000.01571.x","volume":"87","author":"G Sebbag","year":"2000","unstructured":"Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87(11):1587\u201393. https:\/\/doi.org\/10.1046\/j.1365-2168.2000.01571.x.","journal-title":"Br J Surg."},{"issue":"4","key":"13973_CR50","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","volume":"21","author":"D Magge","year":"2014","unstructured":"Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21(4):1159\u201365. https:\/\/doi.org\/10.1245\/s10434-013-3358-y.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"13973_CR51","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1245\/aso.2006.05.041","volume":"13","author":"C Brigand","year":"2006","unstructured":"Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13(3):405\u201312. https:\/\/doi.org\/10.1245\/aso.2006.05.041.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"13973_CR52","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1245\/s10434-012-2651-5","volume":"20","author":"NP Schaub","year":"2013","unstructured":"Schaub NP, Alimchandani M, Quezado M, et al. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol. 2013;20(2):555\u201361. https:\/\/doi.org\/10.1245\/s10434-012-2651-5.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"13973_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.suronc.2014.12.002","volume":"24","author":"J Hubert","year":"2015","unstructured":"Hubert J, Thiboutot E, Dub\u00e8 P, Cloutier AS, Drolet P, Sideris L. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis. Surg Oncol. 2015;24(1):41\u20136. https:\/\/doi.org\/10.1016\/j.suronc.2014.12.002.","journal-title":"Surg Oncol."},{"issue":"11","key":"13973_CR54","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1245\/s10434-018-6631-2","volume":"25","author":"B Malgras","year":"2018","unstructured":"Malgras B, Gayat E, Aoun O, et al. Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC): the RENAPE study. Ann Surg Oncol. 2018;25(11):3271\u20139. https:\/\/doi.org\/10.1245\/s10434-018-6631-2.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"13973_CR55","first-page":"25","volume":"4","author":"AU Blackham","year":"2012","unstructured":"Blackham AU, Levine EA. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Eur J Clin Med Oncol. 2012;4(2):25\u201332.","journal-title":"Eur J Clin Med Oncol."},{"issue":"6","key":"13973_CR56","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","volume":"153","author":"HR Alexander","year":"2013","unstructured":"Alexander HR, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153(6):779\u201386. https:\/\/doi.org\/10.1016\/j.surg.2013.01.001.","journal-title":"Surgery."},{"issue":"4","key":"13973_CR57","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/000313481408000415","volume":"80","author":"SJ Shetty","year":"2014","unstructured":"Shetty SJ, Bathla L, Govindarajan V, Thomas P, Loggie BW. Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg. 2014;80(4):348\u201352. https:\/\/doi.org\/10.1177\/000313481408000415.","journal-title":"Am Surg."},{"issue":"10","key":"13973_CR58","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1245\/s10434-010-1080-6","volume":"17","author":"AU Blackham","year":"2010","unstructured":"Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010;17(10):2720\u20137. https:\/\/doi.org\/10.1245\/s10434-010-1080-6.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"13973_CR59","first-page":"174","volume":"3","author":"GY Ma","year":"1997","unstructured":"Ma GY, Bartlett DL, Reed E, et al. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am. 1997;3(3):174\u20139.","journal-title":"Cancer J Sci Am."},{"issue":"2","key":"13973_CR60","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1515\/pp-2017-0003","volume":"2","author":"KV der Speeten","year":"2017","unstructured":"der Speeten KV, Lemoine L, Sugarbaker P. Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice. Pleura Peritoneum. 2017;2(2):63\u201372. https:\/\/doi.org\/10.1515\/pp-2017-0003.","journal-title":"Pleura Peritoneum."},{"issue":"4","key":"13973_CR61","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.soc.2012.07.013","volume":"21","author":"KVD Speeten","year":"2012","unstructured":"Speeten KVD, Stuart OA, Sugarbaker PH. Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy. Surg Oncol Clin N Am. 2012;21(4):577\u201397. https:\/\/doi.org\/10.1016\/j.soc.2012.07.013.","journal-title":"Surg Oncol Clin N Am."},{"issue":"14","key":"13973_CR62","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/jco.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344. https:\/\/doi.org\/10.1200\/jco.2003.11.136.","journal-title":"J Clin Oncol."},{"issue":"2","key":"13973_CR63","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","volume":"64","author":"G Carteni","year":"2009","unstructured":"Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma \u2013 results from the international expanded access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64(2):211\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2008.08.013.","journal-title":"Lung Cancer."},{"issue":"1","key":"13973_CR64","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3816\/clc.2005.n.020","volume":"7","author":"PA J\u00e4nne","year":"2005","unstructured":"J\u00e4nne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7(1):40\u20136. https:\/\/doi.org\/10.3816\/clc.2005.n.020.","journal-title":"Clin Lung Cancer."},{"issue":"1","key":"13973_CR65","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1245\/s10434-018-6337-5","volume":"1","author":"HR Alexander","year":"2018","unstructured":"Alexander HR, Li CY, Kennedy TJ. Current management and future opportunities for peritoneal metastases: peritoneal mesothelioma. Ann Surg Oncol. 2018;1(1):386\u201396. https:\/\/doi.org\/10.1245\/s10434-018-6337-5.","journal-title":"Ann Surg Oncol."},{"key":"13973_CR66","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jclinepi.2018.11.025","volume":"108","author":"R Brignardello-Petersen","year":"2018","unstructured":"Brignardello-Petersen R, Mustafa RA, Siemieniuk RAC, et al. GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence. J Clin Epidemiol. 2018;108:77\u201385. https:\/\/doi.org\/10.1016\/j.jclinepi.2018.11.025.","journal-title":"J Clin Epidemiol."},{"issue":"4","key":"13973_CR67","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/sla.0000000000003036","volume":"269","author":"SA Antoniou","year":"2019","unstructured":"Antoniou SA, Tsokani S, Mavridis D, et al. Guideline Assessment Project: filling the GAP in surgical guidelines: quality improvement initiative by an international working group. Ann Surg. 2019;269(4):642\u201351. https:\/\/doi.org\/10.1097\/sla.0000000000003036.","journal-title":"Ann Surg."},{"key":"13973_CR68","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12661-3","author":"LF Liesenfeld","year":"2022","unstructured":"Liesenfeld LF, Quiring E, Al-Saeedi M, Nusshag C, B\u00fcchler MW, Schneider M. Extensive peritonectomy is an independent risk factor for cisplatin HIPEC-induced acute kidney injury. Ann Surg Oncol. 2022. https:\/\/doi.org\/10.1245\/s10434-022-12661-3.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13973-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13973-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13973-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T19:07:47Z","timestamp":1696878467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13973-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,23]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["13973"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13973-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,23]]},"assertion":[{"value":"31 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}